Physiomics PLC Notice of Results and Investor Presentation (7728L)
15 Septiembre 2021 - 1:00AM
UK Regulatory
TIDMPYC
RNS Number : 7728L
Physiomics PLC
15 September 2021
15 September 2021
Physiomics plc
("Physiomics") or ("the Company")
Notice of Results and Investor Presentation
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions, is pleased to
announce that it will publish its results for the full year ending
30 June 2021 on Thursday, 30 September.
Dr Jim Millen, CEO of Physiomics, will provide a live
presentation relating to the Company's full year results via the
Investor Meet Company platform on 30 September at 2pm BST. The
presentation is open to all existing and potential shareholders.
Questions can be submitted pre-event via your the 'Investor Meet
Company' dashboard up until 9:00 a.m. the day before the meeting or
at any time during the live presentation.
Investors who already follow Physiomics plc on the Investor Meet
Company platform will automatically be invited. Potential investors
can sign up to 'Investor Meet Company' for free and register to
join the presentation via
https://www.investormeetcompany.com/physiomics-plc/register-investor
.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFZGMLVDVGMZM
(END) Dow Jones Newswires
September 15, 2021 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024